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Abstract
Background and Purpose: American Urological Association guidelines endorse partial nephrectomy as the
preferred treatment for patients with small renal masses, while considering patients with significant co-
morbidities potential candidates for ablative therapy. We compared perioperative, renal functional, and onco-
logic outcomes of renal cryoablation and robot-assisted partial nephrectomy (RAPN) based on our long-term
institutional experience.
Patients and Methods: A retrospective review evaluated 267 patients who underwent laparoscopic or percu-
taneous cryoablation ( July 2000–June 2011) and 233 patients who underwent RAPN ( June 2007–September 2012)
for enhancing renal masses at Washington University.
Results: The perioperative complication rate was 8.6% in the cryoablation group vs 9.4% in the RAPN group
(P = 0.75). There was no significant difference in complication risk between the two treatment modalities on
multivariate analysis. Estimated glomerular filtration rate (eGFR) at last follow-up was 6% lower than preop-
erative eGFR in the cryoablation group and 13% lower in the RAPN group (P < 0.01). The advantage of
cryoablation in preserving renal function persisted on multivariate analysis (P= 0.02). In patients with patho-
logically proven renal-cell carcinoma, 5-year Kaplan-Meier disease-free survival (DFS), cancer-specific survival
(CSS), and overall survival was 83.1%, 96.4%, and 77.1% in the cryoablation cohort vs 100%, 100%, and 91.7% in
the RAPN group. Mean time to recurrence was 16.2 months (range 0.03–42.0 mos). Cryoablation was associated
with increased recurrence risk (hazard ratio [HR] = 11.4, P = 0.01) on multivariate analysis.
Conclusions: Cryoablation and RAPN are safe alternatives for managing renal masses amenable to nephron-
sparing interventions, offering acceptable morbidity and excellent renal preservation. While RAPN offers
improved DFS, for those willing to undergo close postoperative monitoring and accept the potential need for re-
treatment of recurrent disease, cryoablation offers excellent long-term CSS.
Introduction
With the widespread use of abdominal imaging, theincidence of newly diagnosed small renal masses
(SRM) has increased by approximately 2.5% to 3% per year
over the last 30 years.1 According to the National Cancer In-
stitute, 60,920 new cases of renal-cell carcinoma (RCC) were
diagnosed in 2011.2 Accompanying the increased incidental
detection of SRM on abdominal imaging, a downward size
and stage migration favoring smaller, stage I tumors has been
observed.3 By 2007, 13.5% of all newly discovered renal
masses were < 2 cm, 37% < 3 cm, and 60% <4 cm.4 Indeed,
incidental, asymptomatic SRM constitute approximately half
of all cases of suspected RCC referred to urologists today.5
Cumulative data emphasizing the significance of renal
preservation,6–9 in concert with data confirming the equiva-
lency of partial nephrectomy and radical nephrectomy with
regard to oncological outcomes,10 provide the basis for cur-
rent American Urological Association (AUA) guidelines that
recommend partial nephrectomy as the preferred treatment
option for managing T1a renal tumors (<4 cm).11 Never-
theless, cryoablation and percutaneous radiofrequency abla-
tion have been increasingly used as alternatives to partial
nephrectomy in the last 10 years. These less invasive thermal
ablationmodalities have a favorablemorbidity profile and are
generally associated with rapid convalescence.12
Compared with radiofrequency ablation, cryoablation ap-
pears to be associated with a decreased incidence of local
cancer recurrence, metastatic progression, and re-treatment
and is, arguably, the most efficacious alternative to partial
nephrectomy when considering ablative treatment op-
tions.13,14 Unfortunately, reports on the long-term oncologic
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and renal functional outcomes of cryoablation are limited.15
Moreover, a head to head comparison of partial nephrectomy
and cryoablation that appropriately controls for prog-
nostically significant baseline tumor and patient characteris-
tics is as scarce in the literature as it is crucial.16 In the current
study, we compared perioperative, renal functional, and on-
cologic outcomes of renal cryoablation and robot-assisted
partial nephrectomy (RAPN) based on our long-term experi-
ence with these alternative treatments at Washington Uni-
versity, while controlling for baseline tumor and patient
characteristics.
Patients and Methods
The study design was approved by the Human Studies
Committee of Washington University. A retrospective review
evaluated 267 patients who underwent laparoscopic (n = 149)
or percutaneous (n = 118) cryoablation from July 2000 to June
2011 and 233 patients who underwent RAPN from June 2007
to September 2012 for contrast-enhancing renal masses that
were concerning for RCC on preoperative imaging (either CT
or MRI) at Washington University. Patient comorbidity and
surgical risk, tumor location and size, and the preference of
the patient and treating surgeon all contributed to the choice
of treatment. In addition to tumor excision and ablation, pa-
tients were offered tumor surveillance as a management op-
tion for their renal tumor.
Surgical technique
We have previously described our techniques for laparo-
scopic cryoablation,15 percutaneous cryoablation,17 and
RAPN.18
Postoperative follow-up
For our cryoablation group, cross-sectional imaging with
and without contrast was obtained at the following post-
procedure intervals: 1 day, 1 month, 3 months, 6 months, 12
months, and then annually. More recently, our follow-up
protocol was reduced to CT or MRI at 3 months post-
procedure and then yearly up to 5 years. For the RAPNgroup,
abdominal CT or MRI and chest radiography, along with
physical examination, were performed at 3 to 6 months
postoperatively and yearly thereafter. At each follow-up in-
terval, serum chemistry, including serum creatinine, was
evaluated.
Data collection and analysis
Data managers and staff physicians compiled data on pa-
tient demographics and tumor characteristics, as well as
perioperative, renal functional, and oncologic outcomes after
cryoablation or RAPN (Table 1).
Postoperative complications were classified using the Cla-
vien classification system.19 Multiple logistic regression
analysis was performed to assess factors predicting increased
risk of perioperative complications (Table 2).
Using the Chronic Kidney Disease Epidemiology Colla-
boration formula,20 we evaluated postoperative changes in
estimated glomerular filtration rate (eGFR) after cryoablation
and RAPN to assess the renal functional outcomes of these
procedures. The paired t test was used to compare preoper-
ative eGFR with eGFR at last follow-up in each treatment
group, and the independent sample t test was used to com-
pare the mean percent decline in postprocedure eGFR in the
two groups. Multiple linear regression analysis identified
variables that predicted improved preservation of eGFR post-
treatment (Table 3).
For the subset of patients with pathologically confirmed,
localized RCC, Kaplan-Meier analysis of disease-free survival
(DFS), cancer-specific survival (CSS), and overall survival
(OS) was performed in each treatment group. The log-rank
test was used to compare DFS, CSS, and OS between the two
groups (Fig. 1). A multivariate Cox proportional hazards
model identified variables that predicted cancer recurrence in
the same patient subset (Table 4).
Statistical analysis was conducted using MedCalc-11.6 and
SPSS 20 software. Statistical significance was defined by a
two-tailed P value of < 0.05.
Results
A comparison of baseline patient and tumor characteristics
and the perioperative, renal functional, and oncologic out-
comes of cryoablation vs RAPN is provided in Table 1. The
perioperative complication rate was 8.6% in the cryoablation
group vs 9.4% in the RAPN group (P= 0.75). Increasing
Charlson Comorbidity Index (CCI) (odds ratio [OR] = 1.4,
P = 0.01) predicted increased perioperative complication risk
on multiple logistic regression analysis (Table 2). Individual
complications in the cryoablation and RAPN groups are
outlined in Table 5.
In the cryoablation group, mean preoperative eGFR was
66.3mL/min/1.73m2 (standard deviation [SD] = 24.7), com-
pared with 61.3mL/min/1.73m2 (SD = 27.0) at last follow-up
(P< 0.01). Mean preoperative eGFR in the RAPN group was
84.5mL/min/1.73m2 (SD = 20.9) vs 73.4mL/min/1.73m2
(SD = 22.4) at last follow-up (P < 0.01). Thus, eGFR decreased
by amean of 6.0% (SD = 29.2) in the cryoablation group vs 13%
(SD = 19.7) in the RAPN group (P< 0.01). On multiple linear
regression analysis, cryoablation (P = 0.02), smaller tumor size
(P= 0.03), and hilar tumor location (P = 0.01) predicted im-
proved renal functional outcomes (Table 3).
In the subset of patients with biopsy-proven, localized
RCC, the 5-year Kaplan-Meier-estimated DFS in the cryoa-
blation cohort was 83.1%; CSS was 96.4%; OS was 77.1%;
respective 5-year survival for pathologically confirmed RCC
in the RAPN groupwas 100%, 100%, and 91.7%. (Fig. 1) Mean
time to treatment failure in the cryoablation group was 16.2
months (SD = 17.9; range 0.03–42.0mos). Cryoablation (haz-
ard ratio [HR] = 11.4, P = 0.01) and endophytic tumor loca-
tion (HR = 46.9, P = 0.01) were the only predictors of cancer
recurrence in a multivariate cox proportional hazards model
(Table 4).
Discussion
Evidence accumulated over the last decade has shown that
partial nephrectomy is not only technically feasible, but also
oncologically equivalent to radical nephrectomy.10 Moreover,
overutilization of radical nephrectomy has been linked to
chronic renal insufficiency,7 which, in turn, has been linked to
increased risk of cardiovascular disease and premature
death.6–9 Accordingly, current AUA guidelines endorse par-
tial nephrectomy as the primary treatment modality for pa-
tients with T1a tumors (< 4 cm) and as an acceptable treatment
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Table 1. Comparison of Patient and Tumor Characteristics as Well as Perioperative,
Renal Functional, and Oncologic Outcomes in Patients Who Underwent Cryoablation
Versus Those Who Underwent Robot-Assisted Partial Nephrectomy
Cryoablation RAPN P value
Patient characteristics
Mean age, years (SD) 69.3 (11.0) 57.4 (11.9) < 0.01
BMI (SD) 30.4 (7.8) 30.1 (6.0) 0.57
Sex
No. male (%) 163/267 (61.0) 127/233 (54.5) 0.14
No. female (%) 104/267 (39.0) 106/233 (45.5)
Mean age-adjusted CCI (SD) 6.5 (2.2) 2.1 (1.8) < 0.01
Tumor characteristics
Mean tumor size, cm (SD) 2.5 (1.0) 2.9 (1.5) < 0.01
Mean nephrometry score (SD) 6.4 (1.7) 7.3 (1.9) £ 0.01
Tumor laterality
Left (%) 127/267 (47.6) 116/232 (51.7) 0.38
Right (%) 138/267 (51.7) 116/232 (48.3)
Bilateral (%) 2/267 (0.7) 0/116 (0)
Tumor polarity
No. upper pole (%) 80/267 (30.0) 50/211 (23.7) £ 0.01
No. midpolar (%) 91/267 (34.0) 102/211 (48.3)
No. lower pole (%) 96/267 (36.0) 59/211 (28.0)
Tumor location
No. anterior (%) 84/267 (31.5) 37/112 (33.0) £ 0.01
No. lateral (%) 49/267 (18.4) 41/112 (36.6)
No. posterior (%) 134/267 (50.2) 34/112 (30.4)
Tumor location
No. exophytic (%) 133/267 (49.8) 80/222 (36.0) £ 0.01
No. mesophytic (%) 93/267 (34.8) -
No. endophytic (%) 41/267 (15.4) 142/222 (64.0)
No. hilar (%) 36/267 (13.5) 26/195 (13.3) 0.96
No. multifocal (%) 23/267 (8.6) 4/233 (1.7) £ 0.01
Tumor pathology
No. RCC (%) 80/153 (52.3) 185/233 (79.4) £ 0.01
No. other (%) 73/153 (47.7) 48/233 (20.6)
Perioperative outcomes
Surgical approach (excluding PCA)
Transperitoneal (%) 111/146 (76.0) 232/233 (99.6) £ 0.01
Retroperitoneal (%) 35/146 (24.0) 1/233 (0.4)
Mean operative time, minutes (SD) 164.8 (60.2) 140.6 (41.6) £ 0.01
No. with hilar clamping (%) 0/267 (0) 215/233 (92.3) £ 0.01
Mean WIT, minutes (SD) 0 (0) 17.2 (8.6) £ 0.01
Mean EBL, mL (SD) 74.2 (100.1) 136.3 (112.2) £ 0.01
No. intraoperative complications (%) 18/249 (7.2) 3/230 (1.3) £ 0.01
No. postoperative complications (%) 6/267 (2.2) 18/233 (7.7) £ 0.01
No. perioperative complications (%) 23/267 (8.6) 22/233 (9.4) 0.75
No. perioperative blood transfusion (%) 4/267 (0.4) 9/233 (3.9) 0.10
Renal functional outcomes
No. with solitary kidney (%) 27/267 (10.1) 3/231 (1.3) £ 0.01
Mean preoperative sCr, mg/dL (SD) 1.2 (0.9) 0.9 (0.3) £ 0.01
Mean sCr on POD #1 (SD) 1.3 (1.1) 1.1 (0.4) 0.03
Mean sCr at last f/u, mg/dL (SD) 1.4 (1.1) 1.1 (0.5) £ 0.01
Mean preoperative eGFR, mL/min/1.73m2 (SD) 66.3 (24.7) 84.5 (20.9) £ 0.01
Mean eGFR at last f/u, mL/min/1.73m2 (SD) 61.3 (27.0) 73.4 (22.4) £ 0.01
Mean % change in eGFR at last f/u (SD) - 6.0 (29.2) - 13.0 (19.7) £ 0.01
Mean creatinine follow-up, months (SD) 35.8 (31.1) 11.8 (16.4) £ 0.01
Oncological outcomes in the subset of patients
with pathologically proven RCC
No. positive surgical margins (%) NA 5/233 (2.1) -
No. with cancer recurrence (%) 10/79 (12.7) 0/185 (0) £ 0.01
No. necessitating re-treatment (%) 9/79 (11.4) 0/185 (0) £ 0.01
Mean radiographic follow-up, months (SD) 39.8 (34.3) 21.9 (18.8) £ 0.01
RAPN= robot-assisted partial nephrectomy; SD= standard deviation; BMI= body mass index; CCI=Charlson Comorbidity Index;
RCC = renal-cell carcinoma; PCA=percutaneous cryoablation; WIT=warm ischemia time; EBL= estimated blood loss; sCr= serum creatinine;
POD =postoperative day; f/u = follow-up; eGFR= estimated glomerular filtration rate.
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alternative for patients with T1b tumors (4–7 cm).
11 Consistent
with AUA guidelines, utilization rates of partial nephrectomy
now approach 90% at many centers of excellence.21
The emergence of minimally invasive thermal ablation
therapies over the past decade has provided patients with a
diagnosis of renal tumors with a nephron-sparing alternative
to partial nephrectomy, which is typically associated with a
favorable morbidity profile and a precipitous postoperative
recovery.12 According to current AUA guidelines, thermal
ablation is an appropriate treatment alternative to partial
nephrectomy in patients who are poor surgical candidates but
desire active treatment and are willing to undergo extended
radiographic surveillance.11
Comparing available thermal ablation modalities, a meta-
analysis by Kunkle and associates13 concluded that cryoa-
blation is associated with superior local and distant cancer
control relative to radiofrequency ablation.14 Notwithstand-
ing the widespread use of cryoablation as an alternative to
extirpative surgery for suspected renal malignancy, data on
the long-term outcomes of this procedure are limited.15 Even
more pronounced is the paucity of direct head to head com-
parisons of the perioperative, renal functional, and oncologic
outcomes of partial nephrectomy and cryoablation, which
appropriately control for prognostically significant baseline
patient and tumor characteristics.16
In a contemporary meta-analysis evaluating previously
published series on outcomes of partial nephrectomy and
laparoscopic renal cryoablation, Klatte and colleagues16 note
that while there appears to be an increased risk of perio-
perative complications (especially ‘‘major complications’’)
Table 2. Multiple Logistic Regression Analysis Evaluating Factors Associated with Increased
Risk of Perioperative Morbidity After Cryoablation or Robot–Assisted Partial Nephrectomy
OR 95% CI P value
Patient characteristics
Sex 1.00 0.35–2.92 0.99
Male (Referent)
Female
Body mass index 1.45 0.50–4.16 0.49
£30 (Referent)
‡30
Age–adjusted CCI (increments of 1) 1.44 1.09–1.91 0.01
Preoperative eGFR, mL/min/1.73m2 2.01 0.53–7.65 0.31
<60 (Referent)
‡60




Tumor size, cm 1.58 0.51–4.94 0.43
<3 (Referent)
‡3
Tumor laterality 1.39 0.51–3.83 0.52
Left (Referent)
Right
Location relative to renal hilum 1.95 0.49–7.78 0.35
Nonhilar (Referent)
Hilar
Exophytic vs mesophytic vs endophytic (Referent) 1.75 0.49–6.23 0.39
Upper pole vs midpolar vs lower pole (Referent) 0.76 0.19–3.03 0.70
Anterior vs lateral vs posterior (Referent) 0.63 0.18–2.26 0.48
Pathology 0.69 0.18–2.70 0.60
Other (Referent)
Renal-cell carcinoma




Treatment modality 3.00 0.58–15.69 0.19
Cryoablation (Referent)
Robot–assisted partial nephrectomy
Surgical approach 0.29 0.03–3.22 0.31
Transperitoneal (Referent)
Retroperitoneal
Operative time, minutes 1.15 0.39–3.43 0.80
<150 (Referent)
‡150
OR= odds ratio; CI= confidence interval; CCI=Charlson Comorbidity Index; eGFR= estimated glomerular filtration rate.
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with partial nephrectomy, compared with laparoscopic
cryoablation, this comparison was subject to significant se-
lection bias. For example, differences in tumor size and loca-
tion between the two treatment groups could not be
accounted for in their meta-analysis.16 In a critique of the
meta-analysis of Klatte and coworkers,16 Novara and col-
leagues22 suggest that insofar as tumors that were treated
with cryoablation were more likely to be exophytic, secluded
from the renal sinus and collecting system, and located at the
lateral border of the kidney, the lower rate of complications
noted in cryoablation series could very possibly be a reflection
of selection bias rather than the result of a less invasive pro-
cedure.22 The absence of a standardized system (eg, the Cla-
vien system19) for defining complications and classifying their
severity among many of the series in the meta-analysis by
Klatte and associates16 further restricts the meaningful com-
parison of complication rates between cryoablation and par-
tial nephrectomy.
The first aim of the current study was to compare the
perioperative complication rates of RAPN and cryoablation,
using a standardized classification system for reporting
complications—namely, the Clavien classification system19—
while controlling for baseline tumor and patient characteris-
tics. In contrast to a recent study by Guillotreau and co-
workers23 that demonstrated increasedmorbiditywith RAPN
(20%) relative to cryoablation (12%),23 perioperative compli-
cations in the current study were similar between the RAPN
and cryoablation groups (9.4% vs 8.6%, P = 0.75). When eval-
uating whether the utilization of RAPN vs cryoablation pre-
dicted perioperative complication risk in amultivariatemodel
that controlled for baseline patient and tumor characteristics,
there was no significant difference in complication risk noted
between these two treatment modalities. Indeed, the only
factor predicting greater risk of perioperative complications
on multiple logistic regression was increasing patient CCI
(OR = 1.4, P = 0.01). Based on the Washington University
Table 3. Multiple Linear Regression Analysis Evaluating Factors Associated with Greater Preservation of Renal
Function (Estimated Glomerular Filtration Rate) After Cryoablation or Robot-Assisted Partial Nephrectomy
Beta-coefficient 95% CI P value
Patient characteristics
Sex 0.13 - 2.60 to17.31 0.15
Male (Referent)
Female
Age, years - 0.07 - 0.63 to 0.31 0.50
Body mass index 0.12 - 0.25 to 1.50 0.16
Age-adjusted CCI - 0.24 - 5.04 to 0.26 0.08
Preoperative sCr, mg/dL 0.16 - 1.85 to 20.19 0.10
Tumor characteristics
Tumor size, cm - 0.19 - 8.44 to - 0.35 0.03
Tumor laterality - 0.08 - 13.63 to 4.31 0.31
Left (Referent)
Right
Location relative to renal hilum 0.23 5.51 to 30.96 0.01
Nonhilar (Referent)
Hilar
Exophytic vs mesophytic vs endophytic (Referent) 0.02 - 9.72 to 12.62 0.80
Upper pole vs middle pole vs lower pole (Referent) 0.03 - 9.64 to 13.55 0.74
Anterior vs lateral vs posterior (Referent) - 0.07 - 16.06 to 6.66 0.42
Pathology 0.06 - 7.62 to 14.58 0.54
Other (Referent)
Renal-cell carcinoma
Multifocality - 0.07 - 30.67 to 14.48 0.48
Unifocal (Referent)
Multifocal




Treatment modality - 0.33 - 36.17 to - 2.53 0.02
Cryoablation (Referent)
Robot-assisted partial nephrectomy
Surgical approach - 0.13 - 31.86 to 5.25 0.16
Transperitoneal (Referent)
Retroperitoneal
Operative time, minutes 0.01 - 0.10 to 0.10 0.94
Estimated blood loss, mL 0.05 - 0.03 to - 0.05 0.59
Length of sCr follow-up, months 0.04 - 0.15 to 0.22 0.69
The outcome variable—defined as the percent change in estimated glomerular filtration rate (eGFR) after treatment—was measured as
follows: (eGFR at last follow-up—preoperative eGFR)/preoperative eGFR.
CI= confidence interval; CCI=Charlson Comorbidity Index; sCr= serum creatinine.
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FIG. 1. Kaplan-Meier anal-
ysis of disease-free survival
(a), cancer-specific survival
(b), and overall survival (c)
after cryoablation (CA) and
robot-assisted partial
nephrectomy (RAPN).
Respective log-rank: P < 0.01,
P = 0.41, P= 0.11.
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experience, one can, therefore, conclude that cryoablation and
RAPN are safe treatment alternatives for the management of
localized renal masses.
The second aim of this study was to compare the long-term
renal functional outcomes of cryoablation and RAPN, con-
trolling for baseline tumor and patient characteristics. It is
noteworthy that partial nephrectomy requires the excision of
a normal renal parenchymal margin and generally involves
clamping of the renal hilum (associated with warm ischemia)
during tumor excision, which may, at least in theory, con-
tribute to a greater decline in renal function relative to
cryoablation. In the current analysis, cryoablation was, in fact,
associated with improved renal functional outcomes
compared with RAPN (6% vs 13.0% respective drop in eGFR
post-treatment, P< 0.01). The advantage of cryoablation in
preserving renal function persisted after controlling for patient
and tumor characteristics on multivariate analysis (P= 0.02).
Interestingly, smaller tumor size (P = 0.03) and hilar tumor
location (P = 0.01) also predicted improved renal functional
outcomes after cryoablation or RAPN on multivariate analy-
sis. While it is not entirely intuitive that hilar location would
be associated with improved renal functional outcomes, one
explanation for this finding is that, compared with more pe-
ripheral cortical tumors, hilar tumors are more likely to oc-
cupy and invade renal sinus fat, and, as such, their ablation or
excision may be associated with decreased loss of adjacent
functionally active renal parenchyma. Similarly, treatment of
smaller tumors would be expected to result in decreased
compromise of adjacent normal renal parenchyma.
In comparing the oncologic outcomes of partial nephrec-
tomy vs cryoablation, Klatte and coworkers16 again note sig-
nificant selection bias, because patients with certain poor
prognostic features—for example, larger tumors and centrally
positioned tumors with an increased predisposition for vas-
cular invasion—were more likely to be treated with partial
nephrectomy than cryoablation. The authors report that their
meta-analysis was unable to account for these important
confounding differences in baseline patient and tumor char-
acteristics between the two treatment groups, because many
of the cryoablation series failed to report these baseline clinical
data. Klatte and colleagues16 also note that the percentage of
pathologically proven RCC was lower in the cryoablation
Table 4. Multivariate Cox Proportional Hazards Model Identifying Variables That Predicted Cancer
Recurrence in the Subset of Patients with Pathologically Confirmed Renal-Cell Carcinoma
Who Underwent Cryoablation or Robot-Assisted Partial Nephrectomy
OR 95% CI P value
Patient characteristics
Sex 2.24 0.41–12.3 0.35
Male (Referent)
Female
Age, years (increments of 1) 1.03 0.93–1.13 0.56
Body mass index 0.53 0.10–2.84 0.46
< 30 (Referent)
‡ 30
Age–adjusted CCI (increments of 1) 0.84 0.54–1.33 0.46




Tumor size, cm 1.63 0.31–8.51 0.56
< 3 (Referent)
‡ 3
Tumor laterality 0.83 0.16–4.17 0.82
Left (Referent)
Right
Location relative to renal hilum 0.31 0.02–4.05 0.37
Nonhilar (Referent)
Hilar
Endophytic vs mesophytic vs exophytic (Referent) 46.95 3.05–722.34 0.01
Upper pole vs midpolar vs lower pole (Referent) 0.16 0.01–2.48 0.19
Anterior vs lateral vs posterior (Referent) 1.12 0.14–8.99 0.92




LCA vs PCA vs RAPN (Referent) 11.41 1.90–68.67 0.01
Intraoperative complication(s) 6.18 0.36–107.22 0.21
No (Referent)
Yes
Length of radiographic follow-up, months (increments of 1) 0.98 0.96–1.01 0.16
OR= odds ratio; CI = confidence interval; CCI=Charlson Comorbidity Index; eGFR= estimated glomerular filtration rate; LCA= laparo-
scopic cryoablation; PCA=percutaneous cryoablation; RAPN= robot-assisted partial nephrectomy.
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series compared with the partial nephrectomy series, which
may also bias their comparison of oncologic outcomes be-
tween these two groups. This is, in part, because partial ne-
phrectomy series were usually confined to tumors in which
RCC was demonstrated on final surgical pathology, while
laparoscopic cryoablation series often included tumors in
which definitive preablation biopsy was not performed.16
The third aim of this study was to compare the long-term
oncologic outcomes of cryoablation and RAPN for the man-
agement of pathologically proven RCC, while accounting and
controlling for differences in baseline patient and tumor
characteristics between the two treatment groups.We report a
cancer recurrence rate of 12.7% in the cryoablation group,
compared with a 0% recurrence rate in the RAPN group
(P < 0.01) (mean radiographic follow-up 39.8 vs 21.9mos, re-
spectively). Our data are consistent with Cleveland Clinic
data that demonstrated a local recurrence rate of 11% after
cryoablation vs 0% after RAPN (P < 0.0001) (mean radio-
graphic follow-up 44.5 vs 4.8mos, respectively).23 Our com-
parative Kaplan-Meier evaluation of DFS, CSS, and OS
demonstrated a statistically significant long-term advantage
in DFS favoring RAPN (P < 0.01), but no significant difference
in CSS (P = 0.41) or OS (P = 0.11) between the two groups (Fig.
1). In a multivariate Cox proportional hazards model con-
trolling for baseline patient and tumor characteristics, the risk
of cancer recurrence remained higher in the cryoablation
group relative to the RAPN group (HR = 11.4, P = 0.01). Of
note, endophytic tumor growth was also associated with in-
creased risk of cancer recurrence (HR = 46.9, P = 0.01) in this
multivariate model. This finding may, in part, reflect the
greater technical difficulty of visualizing and accessing en-
dophytic tumors, as well as the potentially increased risk of
vascular and lymphatic involvement that an endophytic/
central tumor location poses.
Table 5. Perioperative Complications in the Laparoscopic Cryoablation, Percutaneous Cryoablation,
and Robot-Assisted Partial Nephrectomy Treatments Groups
Intraoperative complications Postoperative complications
LCA
Conversion to hand-assisted LCA because of
difficult visualization
Perinephric hematoma managed conservatively
(Clavien I)
2 cases of small liver laceration managed
conservatively
Atrial fibrillation with rapid ventricular response
medically managed (Clavien II)
4 cases of renal parenchymal fracture—3 managed
conservatively and 1 necessitating PRBC transfusion
Lower extremity DVT managed with angiographic
administration of tPA (Clavien IIIa)
3 cases of hemorrhage—2 managed conservatively
and 1 necessitating PRBC transfusion and
subsequent renal artery angioembolization after a
prolonged ICU course
Non-ST-elevation myocardial infarction (Clavien IVa)
Pulmonary embolism (Clavien IVa)
PCA
Renal parenchymal fracture 2 cases of perinephric hematoma necessitating PRBC
transfusion (Clavien II)5 cases of perinephric hematoma—all managed
conservatively Duodenal-ureteral fistula with retroperitoneal abscess
necessitating abscess drainage, percutaneous
nephrostomy tube placement, and placement of a
duodenal drain and J-tube (Clavien IIIa)
Pneumothorax managed nonoperatively
Partial splenic infarction
Oxygen desaturation with supplementary oxygen
requirement
Apnea necessitating abortion of the procedure
RAPN
Hemorrhage from a missed renal artery Readmission for psychiatric issues (Clavien I)
Traumatic nasogastric tube placement necessitating
upper gastrointestinal tract endoscopy, which was
negative for acute injury
Readmission for pain (Clavien I)
Serosal bowel tear repaired with 8 partial thickness
longitudinal sutures
2 cases of ileus managed conservatively (Clavien I)
Acute renal failure in a patient with CKD managed
conservatively (Clavien I)
6 cases of PRBC transfusion (Clavien II)
Atrial fibrillation medically managed (Clavien II)
Hypertensive crisis medically managed (Clavien II)
Fluid overload medically managed (Clavien II)
DVT medically managed (Clavien II)
2 cases of pseudoaneurysm necessitating
angioembolization (Clavien IIIa)
Urinary leakage necessitatng percutaneous drainage
(Clavien IIIa)
2 cases of non-ST-elevation myocardial infarction
(Clavien IVa)
DVT with pulmonary embolism (Clavien IVa)
LCA= laparoscopic cryoablation; DVT=deep vein thrombosis; tPA= tissue plasminogen activator; PRBC=packed red blood cells;
ICU = intensive care unit; PCA=percutaneous cryoablation; RAPN= robot-assisted partial nephrectomy; CKD= chronic kidney disease.
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Several limitations of this study should be addressed. First,
this study is a retrospective analysis based largely on review
of patient charts. Unavailable data and patient loss to follow-
up may potentially impact our overall outcomes. Another
limitation of the current study is the longer duration of follow-
up in the cryoablation group relative to the RAPN group,
which may, in turn, lead to ‘‘follow-up bias.’’ Furthermore,
because the ascertainment of our study data points predates
the creation of standardized scoring systems for evaluation of
tumor complexity,24 appraisal of a tumor complexity score
was not feasible in a number of our cryoablation patients. It
should be noted, however, that this limitation applies to es-
sentially all previous studies assessing long-term outcomes of
cryoablation.25–28 Despite the inconsistent reporting of a
scoring system defining tumor complexity in the current
study, individual tumor characteristics (eg, size and location)
were appropriately controlled for when comparing outcomes
between the cryoablation and RAPN groups.
Another potential limitation of this study is our reliance on
radiographic assessment of tumor enhancement, without
pathologic tissue corroboration, to define tumor recurrence in
the cryoablation treatment group. We acknowledge that the
absence of enhancement on cross-sectional imaging does not
guarantee the absence of residual tumor cells and, alterna-
tively, that recurrence of enhancement on follow-up imaging
may occur without tumor recurrence. Nevertheless, we be-
lieve that these diagnostic constraints—inherent to any study
of ablative therapy—would not be overcome by performing
diagnostic postprocedural biopsies given the incapacity of
selective tissue sampling to encompass the tumor bed in its
entirety and the heterogeneous nature of the ablated tumor.
The absence of diagnostic pathology in 82% of our percu-
taneous cryoablation patients, which limited the number of
cryoablation patients with confirmed RCC that could be in-
cluded in our oncologic outcomes assessment, is another
study limitation. Because routine diagnostic tumor biopsies
may contribute to potentially increased risk of bleeding, as
well as reduced visualization, without influencing treatment
decisions, we elected not to obtain tissue biopsy during our
initial percutaneous cryoablation procedures. With increasing
experience performing percutaneous cryoablation, however,
we have altered our practice to include diagnostic biopsies
when performing this procedure. Consistent gathering of
pathologic data will certainly facilitate the evaluation of on-
cologic outcomes of percutaneous cryoablation in future
studies.
Conclusion
Cryoablation and RAPN are safe treatment alternatives for
managing renal masses amenable to a nephron-sparing pro-
cedure, offering significant preservation of renal function with
acceptable morbidity. While RAPN offers improved DFS, for
patients who are prepared to undergo close postoperative
monitoring and who accept the potential need to undergo
salvage treatment in the case of tumor recurrence, cryoablation
offers excellent long-term CSS. Patients with compromised
health statuswho desire active treatment but are notmedically
eligible for major surgery involving renal parenchymal inci-
sion are ideal candidates for cryoablation. Additional long-
term follow-up and well-designed prospective comparative
studies are needed to corroborate these findings.
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RAPN¼ robot-assisted partial nephrectomy
RCC¼ renal-cell carcinoma
SD¼ standard deviation
SRM¼ small renal masses
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